ProCE Banner Activity

Slideset: Pharmacotherapy of Premenstrual, Perimenopausal, and Postpartum Depression

Slideset Download

These slides are from a presentation that articulates the criteria for diagnosis of PMDD and options for treatment, describes prevalence of depression in pregnancy and postpartum and management considerations related to pregnancy and breastfeeding, utilizes the Edinburgh Postnatal Depression Scale to screen for depressive symptoms in perinatal and postpartum women, and explains the factors important in identification and treatment of perimenopausal depression.

Released: December 08, 2021

Share

Faculty

Anita H. Clayton

Anita H. Clayton, MD, DLFAPA, IF

Wilford W. Spradlin Professor and Chair
Department of Psychiatry & Neurobehavioral Sciences
Professor of Clinical Obstetrics & Gynecology
University of Virginia School of Medicine
Charlottesville, Virginia

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from

Independent Educational Activity

Faculty Disclosure

Primary Author

Anita H. Clayton, MD, DLFAPA, IF

Wilford W. Spradlin Professor and Chair
Department of Psychiatry & Neurobehavioral Sciences
Professor of Clinical Obstetrics & Gynecology
University of Virginia School of Medicine
Charlottesville, Virginia

Anita H. Clayton, MD, DLFAPA, IF: grants: Daré Bioscience, Janssen, Neumora Therapeutics, Otsuka, Relmada Therapeutics; consultant/advisor: AbbVie, Biogen, Brii Biosciences, Fabre-Kramer, Initiator Pharma, Janssen Research & Development, Mycomedica Life Sciences, PureTech Health, Reunion Neuroscience, S1 Biopharma, Sage Therapeutics, Sertsei Pharmaceuticals, Vella Bioscience; stock/stock options: Euthymics, S1 Biopharma.